1
|
Rodrigo MJ, Cardiel MJ, Fraile JM, Mayoral JA, Pablo LE, Garcia-Martin E. Laponite for biomedical applications: An ophthalmological perspective. Mater Today Bio 2024; 24:100935. [PMID: 38239894 PMCID: PMC10794930 DOI: 10.1016/j.mtbio.2023.100935] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 12/20/2023] [Accepted: 12/27/2023] [Indexed: 01/22/2024] Open
Abstract
Clay minerals have been applied in biomedicine for thousands of years. Laponite is a nanostructured synthetic clay with the capacity to retain and progressively release drugs. In recent years there has been a resurgence of interest in Laponite application in various biomedical areas. This is the first paper to review the potential biomedical applications of Laponite in ophthalmology. The introduction briefly covers the physical, chemical, rheological, and biocompatibility features of different routes of administration. After that, emphasis is placed on 1) drug delivery for antibiotics, anti-inflammatories, growth factors, other proteins, and cancer treatment; 2) bleeding prevention or treatment; and 3) tissue engineering through regenerative medicine using scaffolds in intraocular and extraocular tissue. Although most scientific research is not performed on the eye, both the findings and the new treatments resulting from that research are potentially applicable in ophthalmology since many of the drugs used are the same, the tissue evaluated in vitro or in vivo is also present in the eye, and the pathologies treated also occur in the eye. Finally, future prospects for this emerging field are discussed.
Collapse
Affiliation(s)
- Maria J. Rodrigo
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain
- Aragon Institute for Health Research (IIS Aragon), GIMSO Research Group, University of Zaragoza (Spain), Avda. San Juan Bosco 13, E-50009 Zaragoza, Spain
| | - Maria J. Cardiel
- Aragon Institute for Health Research (IIS Aragon), GIMSO Research Group, University of Zaragoza (Spain), Avda. San Juan Bosco 13, E-50009 Zaragoza, Spain
- Department of Pathology, Lozano Blesa University Hospital, Zaragoza, Spain
| | - Jose M. Fraile
- Institute for Chemical Synthesis and Homogeneous Catalysis (ISQCH), Faculty of Sciences, University of Zaragoza–CSIC, C/Pedro Cerbuna 12, 50009 Zaragoza, Spain
| | - Jose A. Mayoral
- Institute for Chemical Synthesis and Homogeneous Catalysis (ISQCH), Faculty of Sciences, University of Zaragoza–CSIC, C/Pedro Cerbuna 12, 50009 Zaragoza, Spain
| | - Luis E. Pablo
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain
- Aragon Institute for Health Research (IIS Aragon), GIMSO Research Group, University of Zaragoza (Spain), Avda. San Juan Bosco 13, E-50009 Zaragoza, Spain
- Biotech Vision SLP (spin-off Company), University of Zaragoza, Spain
| | - Elena Garcia-Martin
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain
- Aragon Institute for Health Research (IIS Aragon), GIMSO Research Group, University of Zaragoza (Spain), Avda. San Juan Bosco 13, E-50009 Zaragoza, Spain
| |
Collapse
|
2
|
Rodrigo MJ, Bravo-Osuna I, Subias M, Montolío A, Cegoñino J, Martinez-Rincón T, Mendez-Martinez S, Aragón-Navas A, Garcia-Herranz D, Pablo LE, Herrero-Vanrell R, del Palomar AP, Garcia-Martin E. Tunable degrees of neurodegeneration in rats based on microsphere-induced models of chronic glaucoma. Sci Rep 2022; 12:20622. [PMID: 36450772 PMCID: PMC9712621 DOI: 10.1038/s41598-022-24954-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Accepted: 11/22/2022] [Indexed: 12/12/2022] Open
Abstract
This study compares four different animal models of chronic glaucoma against normal aging over 6 months. Chronic glaucoma was induced in 138 Long-Evans rats and compared against 43 aged-matched healthy rats. Twenty-five rats received episcleral vein sclerosis injections (EPIm cohort) while the rest were injected in the eye anterior chamber with a suspension of biodegradable microspheres: 25 rats received non-loaded microspheres (N-L Ms cohort), 45 rats received microspheres loaded with dexamethasone (MsDexa cohort), and 43 rats received microspheres co-loaded with dexamethasone and fibronectin (MsDexaFibro cohort). Intraocular pressure, neuroretinal function, structure and vitreous interface were evaluated. Each model caused different trends in intraocular pressure, produced specific retinal damage and vitreous signals. The steepest and strongest increase in intraocular pressure was seen in the EPIm cohort and microspheres models were more progressive. The EPIm cohort presented the highest vitreous intensity and percentage loss in the ganglion cell layer, the MsDexa cohort presented the greatest loss in the retinal nerve fiber layer, and the MsDexaFibro cohort presented the greatest loss in total retinal thickness. Function decreased differently among cohorts. Using biodegradable microspheres models it is possible to generate tuned neurodegeneration. These results support the multifactorial nature of glaucoma based on several noxa.
Collapse
Affiliation(s)
- María Jesús Rodrigo
- grid.411106.30000 0000 9854 2756Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain ,grid.417198.20000 0000 8497 6529Thematic Research Network in Ophthalmology (Oftared), Carlos III National Institute of Health, Madrid, Spain ,grid.11205.370000 0001 2152 8769Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragón), University of Zaragoza, Zaragoza, Spain
| | - Irene Bravo-Osuna
- grid.4795.f0000 0001 2157 7667Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain ,grid.417198.20000 0000 8497 6529Thematic Research Network in Ophthalmology (Oftared), Carlos III National Institute of Health, Madrid, Spain ,Health Research Institute of the San Carlos Clinical Hospital (IdISSC), Madrid, Spain
| | - Manuel Subias
- grid.411106.30000 0000 9854 2756Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain ,grid.11205.370000 0001 2152 8769Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragón), University of Zaragoza, Zaragoza, Spain
| | - Alberto Montolío
- grid.11205.370000 0001 2152 8769Biomaterials Group, Aragon Engineering Research Institute (I3a), University of Zaragoza, Zaragoza, Spain ,grid.11205.370000 0001 2152 8769Department of Mechanical Engineering, University of Zaragoza, Zaragoza, Spain
| | - José Cegoñino
- grid.11205.370000 0001 2152 8769Biomaterials Group, Aragon Engineering Research Institute (I3a), University of Zaragoza, Zaragoza, Spain ,grid.11205.370000 0001 2152 8769Department of Mechanical Engineering, University of Zaragoza, Zaragoza, Spain
| | - Teresa Martinez-Rincón
- grid.411106.30000 0000 9854 2756Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain ,grid.11205.370000 0001 2152 8769Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragón), University of Zaragoza, Zaragoza, Spain
| | - Silvia Mendez-Martinez
- grid.411106.30000 0000 9854 2756Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain ,grid.11205.370000 0001 2152 8769Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragón), University of Zaragoza, Zaragoza, Spain
| | - Alba Aragón-Navas
- grid.4795.f0000 0001 2157 7667Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain ,grid.417198.20000 0000 8497 6529Thematic Research Network in Ophthalmology (Oftared), Carlos III National Institute of Health, Madrid, Spain ,Health Research Institute of the San Carlos Clinical Hospital (IdISSC), Madrid, Spain
| | - David Garcia-Herranz
- grid.4795.f0000 0001 2157 7667Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain ,grid.417198.20000 0000 8497 6529Thematic Research Network in Ophthalmology (Oftared), Carlos III National Institute of Health, Madrid, Spain ,Health Research Institute of the San Carlos Clinical Hospital (IdISSC), Madrid, Spain
| | - Luis Emilio Pablo
- grid.411106.30000 0000 9854 2756Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain ,grid.417198.20000 0000 8497 6529Thematic Research Network in Ophthalmology (Oftared), Carlos III National Institute of Health, Madrid, Spain ,grid.11205.370000 0001 2152 8769Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragón), University of Zaragoza, Zaragoza, Spain
| | - Rocío Herrero-Vanrell
- grid.4795.f0000 0001 2157 7667Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain ,grid.417198.20000 0000 8497 6529Thematic Research Network in Ophthalmology (Oftared), Carlos III National Institute of Health, Madrid, Spain ,Health Research Institute of the San Carlos Clinical Hospital (IdISSC), Madrid, Spain
| | - Amaya Pérez del Palomar
- grid.11205.370000 0001 2152 8769Biomaterials Group, Aragon Engineering Research Institute (I3a), University of Zaragoza, Zaragoza, Spain ,grid.11205.370000 0001 2152 8769Department of Mechanical Engineering, University of Zaragoza, Zaragoza, Spain
| | - Elena Garcia-Martin
- grid.411106.30000 0000 9854 2756Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain ,grid.417198.20000 0000 8497 6529Thematic Research Network in Ophthalmology (Oftared), Carlos III National Institute of Health, Madrid, Spain ,grid.11205.370000 0001 2152 8769Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragón), University of Zaragoza, Zaragoza, Spain ,C/Padre Arrupe, Servicio de Oftalmología, Edificio de Consultas Externas, Planta 1, 50009 Zaragoza, Spain
| |
Collapse
|
3
|
Chauhan A, Fitzhenry L, Serro AP. Recent Advances in Ophthalmic Drug Delivery. Pharmaceutics 2022; 14:pharmaceutics14102075. [PMID: 36297511 PMCID: PMC9606937 DOI: 10.3390/pharmaceutics14102075] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Accepted: 09/23/2022] [Indexed: 11/16/2022] Open
Affiliation(s)
- Anuj Chauhan
- Chemical and Biological Engineering, Colorado School of Mines, Golden, CO 80401, USA
| | - Laurence Fitzhenry
- Ocular Therapeutics Research Group (OTRG), Pharmaceutical and Molecular Biotechnology Research Centre, Department of Science, South East Technological University, X91 K0EK Waterford, Ireland
| | - Ana Paula Serro
- Centro de Química Estrutural, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal
- Correspondence:
| |
Collapse
|
4
|
Rodrigo MJ, Subías M, Montolío A, Méndez-Martínez S, Martínez-Rincón T, Arias L, García-Herranz D, Bravo-Osuna I, Garcia-Feijoo J, Pablo L, Cegoñino J, Herrero-Vanrell R, Carretero A, Ruberte J, Garcia-Martin E, Pérez del Palomar A. Analysis of Parainflammation in Chronic Glaucoma Using Vitreous-OCT Imaging. Biomedicines 2021; 9:biomedicines9121792. [PMID: 34944608 PMCID: PMC8698891 DOI: 10.3390/biomedicines9121792] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 11/22/2021] [Accepted: 11/25/2021] [Indexed: 11/25/2022] Open
Abstract
Glaucoma causes blindness due to the progressive death of retinal ganglion cells. The immune response chronically and subclinically mediates a homeostatic role. In current clinical practice, it is impossible to analyse neuroinflammation non-invasively. However, analysis of vitreous images using optical coherence tomography detects the immune response as hyperreflective opacities. This study monitors vitreous parainflammation in two animal models of glaucoma, comparing both healthy controls and sexes over six months. Computational analysis characterizes in vivo the hyperreflective opacities, identified histologically as hyalocyte-like Iba-1+ (microglial marker) cells. Glaucomatous eyes showed greater intensity and number of vitreous opacities as well as dynamic fluctuations in the percentage of activated cells (50–250 microns2) vs. non-activated cells (10–50 microns2), isolated cells (10 microns2) and complexes (>250 microns2). Smaller opacities (isolated cells) showed the highest mean intensity (intracellular machinery), were the most rounded at earlier stages (recruitment) and showed the greatest change in orientation (motility). Study of vitreous parainflammation could be a biomarker of glaucoma onset and progression.
Collapse
Affiliation(s)
- María Jesús Rodrigo
- Department of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (M.S.); (S.M.-M.); (T.M.-R.); (L.A.); (L.P.); (E.G.-M.)
- Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), 50009 Zaragoza, Spain
- National Ocular Pathology Network (OFTARED), Carlos III Health Institute, 28040 Madrid, Spain;
- Correspondence: ; Tel.: +34-976765558; Fax: +34-976566234
| | - Manuel Subías
- Department of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (M.S.); (S.M.-M.); (T.M.-R.); (L.A.); (L.P.); (E.G.-M.)
- Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), 50009 Zaragoza, Spain
| | - Alberto Montolío
- Biomaterials Group, Aragon Engineering Research Institute (I3A), University of Zaragoza, 50018 Zaragoza, Spain; (A.M.); (J.C.); (A.P.d.P.)
- Department of Mechanical Engineering, University of Zaragoza, 50018 Zaragoza, Spain
| | - Silvia Méndez-Martínez
- Department of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (M.S.); (S.M.-M.); (T.M.-R.); (L.A.); (L.P.); (E.G.-M.)
- Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), 50009 Zaragoza, Spain
| | - Teresa Martínez-Rincón
- Department of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (M.S.); (S.M.-M.); (T.M.-R.); (L.A.); (L.P.); (E.G.-M.)
- Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), 50009 Zaragoza, Spain
| | - Lorena Arias
- Department of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (M.S.); (S.M.-M.); (T.M.-R.); (L.A.); (L.P.); (E.G.-M.)
- Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), 50009 Zaragoza, Spain
| | - David García-Herranz
- Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid (UCM), 28040 Madrid, Spain;
- Health Research Institute of the San Carlos Clinical Hospital (IdISSC), 28040 Madrid, Spain
- University Institute of Industrial Pharmacy (IUFI), School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain;
| | - Irene Bravo-Osuna
- University Institute of Industrial Pharmacy (IUFI), School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain;
| | - Julian Garcia-Feijoo
- Department of Ophthalmology, San Carlos Clinical Hospital, UCM, 28040 Madrid, Spain;
| | - Luis Pablo
- Department of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (M.S.); (S.M.-M.); (T.M.-R.); (L.A.); (L.P.); (E.G.-M.)
- Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), 50009 Zaragoza, Spain
- National Ocular Pathology Network (OFTARED), Carlos III Health Institute, 28040 Madrid, Spain;
| | - José Cegoñino
- Biomaterials Group, Aragon Engineering Research Institute (I3A), University of Zaragoza, 50018 Zaragoza, Spain; (A.M.); (J.C.); (A.P.d.P.)
- Department of Mechanical Engineering, University of Zaragoza, 50018 Zaragoza, Spain
| | - Rocio Herrero-Vanrell
- National Ocular Pathology Network (OFTARED), Carlos III Health Institute, 28040 Madrid, Spain;
- University Institute of Industrial Pharmacy (IUFI), School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain;
| | - Ana Carretero
- Centre for Animal Biotechnology and Gene Therapy (CBATEG), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; (A.C.); (J.R.)
- CIBER for Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029 Madrid, Spain
- Department of Animal Health and Anatomy, School of Veterinary Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - Jesus Ruberte
- Centre for Animal Biotechnology and Gene Therapy (CBATEG), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain; (A.C.); (J.R.)
- CIBER for Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029 Madrid, Spain
- Department of Animal Health and Anatomy, School of Veterinary Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - Elena Garcia-Martin
- Department of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain; (M.S.); (S.M.-M.); (T.M.-R.); (L.A.); (L.P.); (E.G.-M.)
- Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), 50009 Zaragoza, Spain
- National Ocular Pathology Network (OFTARED), Carlos III Health Institute, 28040 Madrid, Spain;
| | - Amaya Pérez del Palomar
- Biomaterials Group, Aragon Engineering Research Institute (I3A), University of Zaragoza, 50018 Zaragoza, Spain; (A.M.); (J.C.); (A.P.d.P.)
- Department of Mechanical Engineering, University of Zaragoza, 50018 Zaragoza, Spain
| |
Collapse
|
5
|
Rodrigo MJ, Martinez-Rincon T, Subias M, Mendez-Martinez S, Pablo LE, Polo V, Aragon-Navas A, Garcia-Herranz D, Feijoo JG, Osuna IB, Herrero-Vanrell R, Garcia-Martin E. Influence of Sex on Neuroretinal Degeneration: Six-Month Follow-Up in Rats With Chronic Glaucoma. Invest Ophthalmol Vis Sci 2021; 62:9. [PMID: 34643665 PMCID: PMC8525827 DOI: 10.1167/iovs.62.13.9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Purpose To evaluate differences by sex in the neuroretina of rats with chronic glaucoma over 24 weeks of follow-up, and to assess by sex the influence on neurodegeneration of different methods of inducing ocular hypertension. Methods Forty-six Long-Evans rats-18 males and 28 females-with induced chronic glaucoma were analyzed. Glaucoma was achieved via 2 models: repeatedly sclerosing the episcleral veins (9 male/14 female) or by injecting poly(lactic-co-glycolic acid) microspheres measuring 20 to 10 µm (Ms20/10) into the anterior chamber (9 male/14 female). The IOP was measured weekly by tonometer; neuroretinal function was recorded by dark/light-adapted electroretinography at baseline and weeks 12 and 24; and structure was analyzed by optical coherence tomography using the retina posterior pole, retinal nerve fiber layer and ganglion cell layer protocols at baseline and weeks 8, 12, 18, and 24. Results Males showed statistically significant (P < 0.05) higher IOP in both chronic glaucoma models, and greater differences were found in the episcleral model at earlier stages. Males with episclerally induced glaucoma showed a statistically higher increase in retinal thickness in optical coherence tomography recordings than females and also when comparing Ms20/10 at 12 weeks. Males showed a higher percentage of retinal nerve fiber layer thickness loss in both models. Ganglion cell layer thickness loss was only detected in the Ms20/10 model. Males exhibited worse dark/light-adapted functionality in chronic glaucoma models, which worsened in the episcleral sclerosis model at 12 weeks, than females. Conclusions Female rats with chronic glaucoma experienced lower IOP and structural loss and better neuroretinal functionality than males. Sex and the ocular hypertension-inducing method influenced neuroretinal degeneration.
Collapse
Affiliation(s)
- Maria J Rodrigo
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.,Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), University of Zaragoza, Spain.,National Ocular Pathology Network (OFTARED), Carlos III Health Institute, Madrid, Spain
| | - Teresa Martinez-Rincon
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.,Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), University of Zaragoza, Spain
| | - Manuel Subias
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.,Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), University of Zaragoza, Spain
| | - Silvia Mendez-Martinez
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.,Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), University of Zaragoza, Spain
| | - Luis E Pablo
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.,Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), University of Zaragoza, Spain.,National Ocular Pathology Network (OFTARED), Carlos III Health Institute, Madrid, Spain
| | - Vicente Polo
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.,Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), University of Zaragoza, Spain
| | - Alba Aragon-Navas
- Ophthalmology Innovation, Therapy and Pharmaceutical Development (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain.,Health Research Institute, San Carlos Clinical Hospital (IdISSC), Madrid, Spain
| | - David Garcia-Herranz
- Ophthalmology Innovation, Therapy and Pharmaceutical Development (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain.,Health Research Institute, San Carlos Clinical Hospital (IdISSC), Madrid, Spain
| | - Julian García Feijoo
- National Ocular Pathology Network (OFTARED), Carlos III Health Institute, Madrid, Spain.,Health Research Institute, San Carlos Clinical Hospital (IdISSC), Madrid, Spain.,Department of Ophthalmology, San Carlos Clinical Hospital, UCM, Madrid, Spain
| | - Irene Bravo Osuna
- National Ocular Pathology Network (OFTARED), Carlos III Health Institute, Madrid, Spain.,Ophthalmology Innovation, Therapy and Pharmaceutical Development (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain.,Health Research Institute, San Carlos Clinical Hospital (IdISSC), Madrid, Spain.,University Institute for Industrial Pharmacy (IUFI), School of Pharmacy, Complutense University of Madrid, Madrid, Spain
| | - Rocio Herrero-Vanrell
- National Ocular Pathology Network (OFTARED), Carlos III Health Institute, Madrid, Spain.,Ophthalmology Innovation, Therapy and Pharmaceutical Development (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain.,Health Research Institute, San Carlos Clinical Hospital (IdISSC), Madrid, Spain.,University Institute for Industrial Pharmacy (IUFI), School of Pharmacy, Complutense University of Madrid, Madrid, Spain
| | - Elena Garcia-Martin
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain.,Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), University of Zaragoza, Spain.,National Ocular Pathology Network (OFTARED), Carlos III Health Institute, Madrid, Spain.,https://orcid.org/0000-0001-6258-2489
| |
Collapse
|